ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last1,981 to 2,000 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Universal PrEP Counselling vs Targeted PrEP Clinics: PrEP Use397 of 2,250

323 of 2,197

2.9 points

0.8 to 5.1

4,447NCT03070600

PrEP Implementation for Mothers in Antenatal Care

Universal PrEP Counselling vs Targeted PrEP Clinics: deaths from any cause2 of 2,250

2 of 2,197

-0.0 points

-0.3 to 0.2

4,447NCT03070600

PrEP Implementation for Mothers in Antenatal Care

Universal PrEP Counselling vs Targeted PrEP Clinics: serious adverse events132 of 2,250

118 of 2,197

0.5 points

-0.9 to 1.9

4,447NCT03070600

PrEP Implementation for Mothers in Antenatal Care

Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): Incidence of Adverse Events for Each Treatment416 of 2,227

429 of 2,219

-0.7 points

-3.0 to 1.7

4,446NCT02135419

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): deaths from any cause55 of 2,227

48 of 2,219

0.3 points

-0.6 to 1.2

4,446NCT02135419

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Arm I (Treatment) vs Arm II (Active Monitoring) (Closed Since SEP2021): serious adverse events370 of 2,227

375 of 2,219

-0.3 points

-2.5 to 1.9

4,446NCT02135419

Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions

Mindfulness-Based Cognitive Therapy vs Brief Mindfulness: serious adverse events30 of 2,220

31 of 2,192

-0.1 points

-0.8 to 0.6

4,412NCT03844321

Healthy Mind Healthy You: A Study of Mindfulness

Colchicine vs Placebo: deaths from any cause5 of 2,195

9 of 2,217

-0.2 points

-0.6 to 0.2

4,412NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Colchicine vs Placebo: serious adverse events108 of 2,195

139 of 2,217

-1.3 points

-2.7 to 0.0

4,412NCT04322682

Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA)

Chemo and Endocrine Therapy vs Endocrine Therapy Alone: serious adverse events14 of 2,062

9 of 2,342

0.3 points

-0.1 to 0.8

4,404NCT01272037

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Canagliflozin 100 mg vs Placebo: deaths from any cause164 of 2,200

193 of 2,197

-1.3 points

-3.0 to 0.3

4,397NCT02065791

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Canagliflozin 100 mg vs Placebo: serious adverse events737 of 2,200

806 of 2,197

-3.2 points

-6.0 to -0.4

4,397NCT02065791

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

MenHibrix Group vs ActHIB Group: serious adverse events157 of 3,278

48 of 1,113

0.5 points

-1.0 to 1.8

4,391NCT00345579

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

Dapa 10 mg vs Placebo: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure for LVEF <60% Subpopulation381 of 2,200

440 of 2,172

-2.9 points

-5.3 to -0.6

4,372NCT03619213

Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.

XAGRID vs Other (Cytoreductives): Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events37 of 1,300

70 of 3,069

0.6 points

-0.4 to 1.7

4,369NCT00567502

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

XAGRID vs Other (Cytoreductives): serious adverse events37 of 1,300

70 of 3,069

0.6 points

-0.4 to 1.7

4,369NCT00567502

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to XAGRID® (Anagrelide Hydrochloride) Compared to Other Treatments

Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin45 of 2,184

123 of 2,167

-3.6 points

-4.8 to -2.5

4,351NCT00141102

Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis

Vitamins vs Placebo: Analysis of Primary Composite Outcome in Participants Randomized Before the 13th Week of Pregnancy144 of 2,181

127 of 2,162

0.7 points

-0.7 to 2.2

4,343NCT00135707

Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS)

3 Months Dual Anti-platelet Therapy vs 12 Months Dual Anti-platelet Therapy: Incidence: Blood Transfusion138 of 2,164

140 of 2,164

-0.1 points

-1.6 to 1.4

4,328NCT03252249

Duration of Dual Anti-Platelet Therapy (DUAL-ACS)

Universal PrEP Counselling vs Targeted PrEP Clinics: Preterm Birth506 of 2,205

309 of 2,101

8.2 points

5.9 to 10.6

4,306NCT03070600

PrEP Implementation for Mothers in Antenatal Care

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=100"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=100

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03070600-689938d0",
        "title": "Universal PrEP Counselling vs Targeted PrEP Clinics: PrEP Use",
        "summary": "397 of 2250 against 323 of 2197; risk difference 2.9 points, 95% interval 0.8 to 5.1; NCT03070600, PrEP Implementation for Mothers in Antenatal Care",
        "record": "/library/comparisons/NCT03070600-689938d0",
        "nct_id": "NCT03070600",
        "kind": "outcome",
        "participants": 4447,
        "risk_difference": {
          "value": 0.0294257826328832,
          "lower": 0.007773936856835039,
          "upper": 0.051037034672771195
        },
        "group_1": "397 of 2,250",
        "group_2": "323 of 2,197",
        "difference": "2.9 points",
        "interval": "0.8 to 5.1",
        "trial_title": "PrEP Implementation for Mothers in Antenatal Care"
      },
      {
        "id": "NCT03070600-deaths",
        "title": "Universal PrEP Counselling vs Targeted PrEP Clinics: deaths from any cause",
        "summary": "2 of 2250 against 2 of 2197; risk difference -0.0 points, 95% interval -0.3 to 0.2; NCT03070600, PrEP Implementation for Mothers in Antenatal Care",
        "record": "/library/comparisons/NCT03070600-deaths",
        "nct_id": "NCT03070600",
        "kind": "deaths",
        "participants": 4447,
        "risk_difference": {
          "value": -0.000021443382390127922,
          "lower": -0.002509450519323683,
          "upper": 0.0024162514123507537
        },
        "group_1": "2 of 2,250",
        "group_2": "2 of 2,197",
        "difference": "-0.0 points",
        "interval": "-0.3 to 0.2",
        "trial_title": "PrEP Implementation for Mothers in Antenatal Care"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=101",
  "request_id": "k2iyU50zhsgjMx2k"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?